---
schema_version: "secwatch.filing_event.v1"
accession: "0001601485-23-000071"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2023-11-03T23:59:59+00:00"
generated_at: "2026-06-08T22:29:10.212855+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Elicio reports ELI-002 Phase 1 data: 87% T cell response, 86% reduced relapse risk; new preclinical data

## Summary
- ELI-002 Phase 1: 87% (20/23) of patients had direct ex vivo mKRAS-specific T cell responses; 100% in vitro.
- T cell response strength correlated with 86% reduced risk of relapse and death in pancreatic/colorectal cancer.
- In 4 patients assessed post-boost, 100% maintained elevated T cell responses, 75% increased further.
- ELI-007 and ELI-008 preclinical: >10-500-fold higher T cell responses vs. conventional comparators in mice.
- Data presented at SITC 2023; supports lymph node-targeting AMP platform for solid tumors.

## SEC filing metadata
- accession: 0001601485-23-000071
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2023-11-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000160148523000071/0001601485-23-000071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000160148523000071/angn-20231103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601485-23-000071
- JSON: https://secwatch.observer/filing/0001601485-23-000071.json
- Plain text: https://secwatch.observer/filing/0001601485-23-000071.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.